The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component

British Journal of Haematology

Volumn 144, Issue 4, 2009, Pages 531-537

  Abuzetun, Jamil Y ^a   Loberiza, Fausto ^b   Vose, Julie ^b   Bierman, Philip ^b   Greg Bociek, R ^b   Enke, Charles ^b   Bast, Martin ^b   Weisenburger, Dennis ^b   Armitage, James O ^b,c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Hodgkin lymphoma; Radiotherapy; Stanford V regimen

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DOXORUBICIN; EPIDEMIOLOGIC METHODS; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 58549089687     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07500.x     Document Type: Article

References (16)

1. AJCC (2002) AJCC Cancer Staging Manual. Springer, New York, NY.
2. Bartlett, N.L., Rosenberg, S.A., Hoppe, R.T., Hancock, S.L. Horning, S.J. (1995) Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. Journal of Clinical Oncology, 13, 1080 1088.
3. Bonadonna, G., Zucali, R., Monfardini, S., De Lena, M. Uslenghi, C. (1975) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer, 36, 252 259.
4. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478 1484.
5. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society, 34, 187 220.
6. DeVita, Jr., V.T., Serpick, A.A. Carbone, P.P. (1970) Combination chemotherapy in the treatment of advanced Hodgkin's disease. Annals of Internal Medicine, 73, 881 895.
7. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.K., Duhmke, E. Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386 2395.
8. Gobbi, P.G., Levis, A., Chisesi, T., Broglia, C., Vitolo, U., Stelitano, C., Pavone, V., Cavanna, L., Santini, G., Merli, F., Liberati, M., Baldini, L., Deliliers, G.L., Angelucci, E., Bordonaro, R. Federico, M. (2005) ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Journal of Clinical Oncology, 23, 9198 9207.
9. Hasenclever, D. Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506 1514.
10. Horning, S.J., Williams, J., Bartlett, N.L., Bennett, J.M., Hoppe, R.T., Neuberg, D. Cassileth, P. (2000) Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. Journal of Clinical Oncology, 18, 972 980.
11. Horning, S.J., Hoppe, R.T., Breslin, S., Bartlett, N.L., Brown, B.W. Rosenberg, S.A. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. Journal of Clinical Oncology, 20, 630 637.
12. Jaffe, E., Harris, N., Stein, H. Vardiman, J. (eds 2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In : World Health Organization Classification of Tumors, pp. 237 253. IARC Press, Lyon.
13. Kaplan, E.L. Meier, P. (1958) Non parametric estimation from incomplete observations. Journal of American Statistics Association, 53, 457 481.
14. Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Rosenberg, S.A., Coltman, C.A. Tubiana, M. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. Cotswolds meeting. Journal of Clinical Oncology, 7, 1630 1636.
15. Peters, V. (1950) A study in survivals in Hodgkin's disease treated radiologically. American Journal of Roentgenology, 63, 299 311.
16. Peters, M.V. Middlemiss, K.C. (1958) A study of Hodgkin's disease treated by irradiation. The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, 79, 114 121.